Assessment of sexual difficulties associated with multi-modal treatment for cervical or endometrial cancer: A systematic review of measurement instruments by White, I. D. et al.
              
City, University of London Institutional Repository
Citation: White, I. D., Sangha, A., Lucas, G. ORCID: 0000-0001-5941-5233 and 
Wiseman, T. (2016). Assessment of sexual difficulties associated with multi-modal treatment 
for cervical or endometrial cancer: A systematic review of measurement instruments. 
Gynecologic Oncology, 143(3), pp. 664-673. doi: 10.1016/j.ygyno.2016.08.332 
This is the accepted version of the paper. 
This version of the publication may differ from the final published 
version. 
Permanent repository link:  http://openaccess.city.ac.uk/id/eprint/23357/
Link to published version: http://dx.doi.org/10.1016/j.ygyno.2016.08.332
Copyright and reuse: City Research Online aims to make research 
outputs of City, University of London available to a wider audience. 
Copyright and Moral Rights remain with the author(s) and/or copyright 
holders. URLs from City Research Online may be freely distributed and 
linked to.
City Research Online:            http://openaccess.city.ac.uk/            publications@city.ac.uk
City Research Online
1 
 
Title: Assessment of Sexual Difficulties Associated with Multi-modal Treatment for Cervical or 
Endometrial Cancer: a systematic review of measurement instruments  
 
Authors:  
Dr. Isabella D. White1 
Amrit Sangha2    
Grace Lucas2 
Professor Theresa Wiseman3  
 
1 Clinical Research Fellow in Psychosexual Practice, Psychological Support Department 
& Health Services Research, The Royal Marsden NHS Foundation Trust, Fulham Road, 
London, SW3 6JJ, UK. Email: isabel.white@rmh.nhs.uk 
2 Research Associate, Health Service Research, The Royal Marsden NHS Foundation 
Trust, London, SW3 6JJ, UK. Email: amrit.sangha@rmh.nhs.uk;grace.lucas@rmh.nhs.uk 
3Clinical Chair of Applied Health in Cancer Care & Strategic Lead for Health Services 
Research, The Royal Marsden NHS Foundation Trust & University of Southampton, 
Highfield, Southampton, SO17 1BJ UK Email: theresa.wiseman@rmh.nhs.uk 
 
 
 
 
Corresponding Author: 
Dr. Isabella D. White, Clinical Research Fellow in Psychosexual Practice,  
The Royal Marsden NHS Foundation Trust, 
Fulham Road, 
London, SW3 6JJ 
UK. 
Email: isabel.white@rmh.nhs.uk 
Tel: +44 (0)20 7811 8522 
Fax: N/A
2 
 
Abstract 
Background: Practitioners and researchers require an outcome measure that accurately 
identifies the range of common treatment-induced changes in sexual function and well-being 
experienced by women after cervical or endometrial cancer. This systematic review critically 
appraised the measurement properties and clinical utility of instruments validated for the 
measurement of female sexual dysfunction (FSD) in this clinical population. 
Methods: 
A bibliographic database search for questionnaire development or validation papers was 
completed and methodological quality and measurement properties of selected studies rated 
using the Consensus-based Standards for the selection of health Measurement Instrument 
(COSMIN) checklist. 
Results: 738 articles were screened, 13 articles retrieved for full text assessment and 7 
studies excluded, resulting in evaluation of 6 papers; 2 QoL and 4 female sexual morbidity 
measures.  
Five of the six instruments omitted one or more dimension of female sexual function and only 
one instrument explicitly measured distress associated with sexual changes as per DSM V 
(APA 2013) diagnostic criteria.  
None of the papers reported measurement error, responsiveness data was available for only 
two instruments, three papers failed to report on criterion validity, and test-retest reliability 
reporting was inconsistent. Heterosexual penile-vaginal intercourse remains the dominant 
sexual activity focus for sexual morbidity PROMS terminology and instruments lack explicit 
reference to solo or non-coital sexual expression or validation in a non-heterosexual sample. 
Four out of six instruments included mediating treatment or illness items such as vaginal 
changes, menopause or altered body image. 
Conclusions:  
Findings suggest that the Female Sexual Function Index (FSFI) remains the most robust 
sexual morbidity outcome measure, for research or clinical use, in sexually active women 
treated for cervical or endometrial cancer.  
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Development of an instrument that measures sexual dysfunction in women who are 
infrequently / not sexually active due to treatment consequences is still required to identify 
women in need of sexual rehabilitation. 
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Introduction  
Worldwide approximately half a million women are diagnosed annually with invasive cervical 
cancer [1] with 5 year survival rates ranging from >80-90% after treatment for stage 1A/1B 
disease in developed countries, and a 62% all stage 5 year relative survival across Europe 
[2]. While rates of cervical cancer in developed countries are in decline, it is estimated that 0.5 
million cases of endometrial cancer will be diagnosed worldwide by 2035, with a 5-year 
survival rate of >80% for stage 1 and a 76% 5 year relative survival for all stages [2,3,4]. 
 Despite treatment advances and improved survival rates, late treatment consequences 
remain under-recognised and under-reported by health professionals and patients alike 
[5,6,7,8]. Although reporting of urinary and bowel effects associated with pelvic radiotherapy 
has become more common, details of treatment-induced female sexual morbidity remain 
limited [9,10,11]. Published studies suggest that 30-63% of women with cervical cancer 
experience sexual difficulties after pelvic radiotherapy [12,13]. Furthermore, the type and 
radicality of pelvic surgery may also influence the extent of sexual recovery achievable 
[14,15,16]. While fewer studies have focused on sexual function after endometrial cancer 
treatment [17,18] evidence suggests that this patient population, previously thought to be at 
low risk, also experience significant sexual dysfunction [19,20]. 
 Treatment-induced physical effects after cervical or endometrial cancer include vaginal 
dryness, fibrosis, stenosis, shortening, vaginal bleeding, menopausal symptoms, skin 
reactions, urinary difficulties, disruption to bowel function and infertility [9,13,18, 21]. 
Furthermore, psychological impacts include anxiety, depression, fear of sexual pain and 
altered femininity [11,22]. Hence, changes in sexual function and well-being associated with 
treatment remain important research and clinical outcomes in their own right [11,23,24].  
 The clinical assessment and management of sexual difficulties after gynaecological 
cancer remains a frequently overlooked aspect of recovery and rehabilitation, with health 
professionals and women themselves having difficulty in raising this topic [11,22]. Clearly, the 
first step towards being able to offer systematic management for the sexual consequences of 
cancer is timely and accurate clinical assessment [25,26].  
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The number of health status questionnaires available for measuring patient reported 
outcomes (PROMS) has increased dramatically over recent decades [26,27]. There is now a 
range of patient self-report questionnaires developed to assess female sexual dysfunction 
(FSD) specifically [23,28] or as one dimension of a broader quality of life (QOL) assessment 
[29,30]. However, many existing questionnaires do not include the full range of organic and 
psychogenic sexual disruptions encountered after gynaecological cancer treatment.  
 In general, disease-, treatment-, or symptom-specific questionnaires are better at 
identifying between-group differences (sensitivity) and changes over time (responsiveness) 
than generic cancer or sexual dysfunction questionnaires [31]. Nevertheless, the challenge 
facing clinicians and researchers is to select the most appropriate instrument that 
demonstrates psychometric rigour [27], reflects the full range of contemporary (DSM V) 
female sexual dysfunction diagnostic categories commonly encountered in gynae-oncology 
[32] and has clinical utility in identifying women most likely to benefit from specialist 
assessment and management [33]. 
 A number of previous reviews have explored the development and use of QOL, 
symptom assessment and sexual function measures in gynaecological [34,35] or cervical 
cancer [29,30] survivors, with some discussion of psychometric rigour and/or clinical utility. 
However, there is a paucity of in-depth systematic reviews conducted to date that specifically 
evaluate the measurement properties and clinical utility of female sexual dysfunction 
questionnaires in women treated by pelvic surgery/radiotherapy for cervical and endometrial 
cancer.  
This systematic review evaluates English language instruments for female sexual dysfunction 
(FSD) in women after pelvic surgery and / or radiotherapy for cervical or endometrial cancer. 
The COSMIN (COnsensus-based Standards for the selection of health Measurement 
INstruments) checklist [36] critically appraised published evidence of the measurement 
properties of these patient self-report instruments and a summary of the clinical utility of 
instruments is included. This paper also adheres to PRISMA (preferred reporting items for 
systematic reviews and meta-analyses) guidelines [37].  
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Methods 
Search Strategy 
The following databases were searched for papers reporting the development or validation of 
questionnaires measuring sexual (dys)function in women with cervical or endometrial cancer:  
Embase (1990-2015), MEDLINE (1990-2015), PsycINFO (1990 -2015), CINAHL (1990-2015), 
BNI (1990-2015), AMED (1990-2015) using Ovid.   
As there have been significant developments in treatment for endometrial and cervical 
cancer, and in the conceptualisation of female sexual [dys]function over recent years, this 
review focused on full text articles published in the English language from 1990 to 2015.   
We used the protocol by Terwee [38] to devise a search strategy with multiple search terms 
addressing the following instrument dimensions: 
1. The construct of interest: Sexual [dys]function 
2. Target population: Female.  
3. Type of instrument: questionnaire, outcome measure or assessment instrument 
4. Measurement properties: based on a search filter for finding studies of assessment 
instrument measurement properties described by Terwee et al [39].  
A preliminary search using cancer as a search term failed to retrieve a number of 
relevant papers of which the review team were aware, leading to the selection of wider search 
parameters to ensure adequate capture of data sources.  
This was followed by a systematic search (Table 1) based on a comprehensive list of possible 
synonyms for each individual search (March 2015). Synonyms combined with the conjunction 
‘OR’ and searches for all four characteristics combined with the conjunction ‘AND’ obtained a 
list of references used to search for relevant papers. Reference lists from relevant studies 
were hand searched and study authors contacted where further information was required.   
Study Selection  
To meet the inclusion criteria for the review, papers needed to report on the development and 
/ or validation of an instrument measuring sexual (dys)function within an identifiable sample  
of women treated for either cervical or endometrial cancer. For an instrument to be included, 
female sexual dysfunction had to be the construct under evaluation within the assessment 
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instrument, although this could be limited to one domain within a wider quality of life (QOL) 
instrument.  
Exclusion criteria included Quality of Life (QoL) or treatment toxicity studies that did not have 
a significant focus on sexual dysfunction and papers with a primary focus on sexual history 
taking or professional / patient communication about sexual impact of illness or treatment or 
body image. Instruments were also excluded if they measured sexual dysfunction in diseases 
or treatment effects unrelated to cervical or endometrial cancer, or where results from a 
cervical or endometrial cancer sub-sample of women was not identifiable [40,41]. 
Two reviewers (GL and AS) independently assessed the titles, abstracts and 
reference lists of studies retrieved by the literature search. In addition, IW reviewed lists of 
included and excluded papers prior to retrieval of full-text articles. Full text articles were then 
individually reviewed against the inclusion criteria (AS and IW) and in the case of 
disagreement, a third reviewer (TW) enabled a consensus decision to be reached.  
Assessment of methodological quality and data extraction   
The rigour of systematic reviews of health status questionnaires is enhanced by the use of 
methodological quality criteria regarding instrument development and evaluation in order to 
identify the most valid and reliable questionnaire for research and clinical use [42]. The 
COSMIN checklist [42] evaluates the methodological rigour of each instrument paper across 
nine measurement properties. Each property criterion was scored on a 4-point rating scale 
(i.e. poor, fair, good or excellent) and an overall score for the methodological quality of the 
reported study determined by taking the lowest criterion rating for that specific measurement 
property.  
Data extraction included relevant data (e.g. design, sample, method, psychometric tests and 
results) as well as the conceptual scope of instruments in measuring FSD as defined in DSM 
V and key factors mediating FSD (see Table 4). The data extraction form was piloted to 
ensure capture of all relevant information.  
Data extraction and assessment of (methodological) quality was carried out 
independently by two reviewers (IW and AS), using criteria agreed in advance, to ensure 
consistency. In the case of disagreement between reviewers, further discussion ensued to 
reach consensus with a third reviewer (TW) acting as final arbiter where necessary. 
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Results 
The search strategy generated 707 unique hits; a further 31 articles were identified via 
reference checking and hand searching. Seven hundred and thirty-eight articles were 
screened; 650 were excluded with 88 titles and abstracts considered for inclusion. 
After reviewing against inclusion and exclusion criteria, a further 75 articles were excluded 
(see figure 1) and 13 full text papers downloaded. This full text review resulted in the 
exclusion of a further seven papers, the rationale for which is summarised in Fig. 1.  
Characteristics of selected instruments 
Six studies reporting the development and/or evaluation of instruments measuring FSD in 
women treated for cervical and or endometrial cancer were subjected to full data extraction 
and application of the COSMIN checklist in this systematic review. Two were QoL measures  
with FSD subscales, developed as disease and treatment specific modules to supplement the 
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 
(EORTC QLQ C30). The EORTC QLQ CX24 addresses morbidities arising from cervical 
cancer treatment whilst the EORTC QLQ EN24 is endometrial cancer specific. One FSD 
measure (FSFI) was validated in a heterogeneous sample of women treated for cancer, 
including cervical/endometrial cancer, two FSD instruments were specific to gynaecological 
cancer (SABIS-G and SVQ) and one instrument was validated in a cervical cancer sample 
alone (GLQ). The characteristics of included studies are summarised in Table 2 and 
evaluation of the instrument’s measurement properties using the COSMIN checklist in Table 
3. This paper offers an outline of each instrument prior to synthesis and evaluation of key 
findings including the conceptual scope (Table 4) and clinical utility (Table 5) of reviewed 
instruments. 
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Female Sexual Function Index (FSFI) 
The Female Sexual Function Index is the most widely used research and clinical instrument 
to measure sexual function in sexually active heterosexual women validated for use in cancer 
survivors [24]. It is a multi-dimensional measure addressing desire, subjective and objective 
(lubrication) arousal, orgasm, sexual pain, and sexual satisfaction.  
The FSFI consists of 19 items scored on an ordinal Likert scale (0 or 1 to 5). Each 
subscale has a maximum score of six, resulting in a maximum overall score of 36 for the 
measure, with high scores indicative of better sexual function and a score of 26 as the clinical 
cut off for diagnosing FSD [43].   
Using the COSMIN checklist (Table 3) the internal consistency reliability score was rated 
excellent (Cronbach alpha subscale scores 0.85 to 0.94, total score 0.94). Content (and 
structural) validity were also rated excellent as exploratory factor analysis yielded a factor 
solution similar to that reported in the original validation studies [28,44]. Five factors 
accounted for 81.4% of the total variance and corresponded well to the six FSFI domains. 
In terms of cross-cultural validation, the FSFI has been validated among FSD samples in 8 
languages other than English, and in English and Chinese oncology samples to date [45,46]. 
Limitations of the FSFI are consistent with other measures of sexual (dys)function 
whereby the validity of instrument scores is undermined when women with little or no recent 
(past 4 weeks) sexual activity are included. The FSFI scoring algorithm does not distinguish 
between women who score zero due to sexual difficulties affecting a particular item / domain, 
versus those who are sexually inactive for reasons unrelated to their cancer treatment [24]. 
The validation sample comprised predominantly women treated for cervical cancer (59%) and 
so discriminant validity may warrant further evaluation. Furthermore, longitudinal data is 
required to demonstrate responsiveness of FSFI scores to change over time. 
The conceptual scope of the FSFI addresses all core dimensions of female sexual 
(dys)function and incorporates solo sexual expression and relationship items, although its 
validity in non-heterosexual women has not been established.  
In terms of clinical utility, the instrument is relatively brief (approx 15 mins to 
complete), uses standard Likert response options and has an established cut off score (<26) 
for diagnosis of FSD [43]. However, the instrument does not incorporate mediating factors 
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prevalent in oncology practice such as specific treatment impacts or intervention use that may 
be helpful to clinicians in determining management or referral options (Tables 4 & 5).  
 
Sexual Adjustment and Body Image Scale- Gynecologic Cancer (SABIS-G)  
The sexual adjustment and body image scale for women with gynaecological cancer 
measures changes in sexuality and body image arising from diagnosis / treatment, and is 
based on an outcome measure originally validated in a surgical breast cancer sample [47,48]. 
SABIS-G is a 7-item measure solely available in English, with three items addressing body 
image and four related to sexual adjustment. Scores range from 1-5, with higher scores 
representing better sexual adjustment.  
Internal consistency rated excellent (Body Image 0.88, Sexual Adjustment 0.91) but 
content validity rated only fair as the scope of this instrument includes body image and limited 
(n=4) sexual adjustment items (Table 4) and hence does not represent a comprehensive 
measure of FSD. Structural and criterion validity rated excellent as the SABIS-G performed as 
expected against selected comparator instruments (Table 3).  
The SABIS-G demonstrated adequate known groups validity, with women who had cervical 
cancer or received chemo-radiation scoring lower, as expected, than other disease types / 
treatment combinations (p = 0.01 / 0.03). While intra class correlation (0.89) was excellent 
(Table 3), overall reliability only scored fair as participant stability in the interim test-retest 
period was not reported.  
As the conceptual scope of the SABIS-G does not measure all dimensions of female sexual 
function (excludes arousal and orgasm) or sexual pain, a common problem after 
gynaecological cancer treatment, it has limited clinical utility as a comprehensive measure of 
female sexual dysfunction.  
Scoring adopts 5-point Likert scales but calculation of an overall weighted sum of 0-100 for 
each subscale is complex for rapid clinical use. Furthermore, a cut-off score for clinically 
significant body image / sexual adjustment difficulties has yet to be determined. Nevertheless, 
this instrument may represent a suitable brief screening instrument to identify the presence or 
absence of body image and sexual adjustment concerns prior to more detailed specialist 
assessment.  
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 European Organisation for Research and Treatment of Cancer Quality of Life 
Questionnaire-Cervical Cancer Module (EORTC QLQ CX-24) 
The Cervical Cancer Module (EORTC QLQ CX-24) comprises of nine QOL domains, five of 
which relate to FSD (Table 4) [49].   
Internal consistency and structural validity were rated poor according to the COSMIN 
checklist, due to the use of multi-trait scaling analysis rather than the preferred method of 
factor analysis [42]. Multi-trait scaling analysis demonstrated high internal consistency for 
three subscales with satisfactory Cronbach alpha coefficients (Symptom Experience 0.72, 
Body Image 0.86; Sexual/Vaginal Functioning 0.87). Convergent and discriminant validity 
scaling errors were below 3%.    
Cross-cultural validity rated poor (Table 3) as confirmatory factor analysis had not 
been used to evaluate cross-cultural validity and results from individual countries were not 
reported. However, the use of item generation and cognitive testing across samples of 
women from nine European countries, Australia, Brazil, Korea and Taiwan and international 
expert panel review enhance the instrument’s content validity [49]. The CX-24 has been 
validated in South Asian [50], Korean [51], Chinese [52], Polish [53] and South African [54] 
samples.  
Limitations of the EORTC QLQ CX-24 include absent test-retest reliability and 
instrument responsiveness data, together with a high non-response rate (>60%) for the 
sexual / vaginal functioning sub-scale, representing sexually inactive women.  
In terms of clinical utility, the QLQ CX-24 can be completed in approximately 15 mins 
and has a simple Likert scoring system, although the instrument-scoring template requires 
linear transformation to a 0-100 scale. As this is a QOL instrument, clinical cut off scores for 
diagnostic purposes are not appropriate.  
The QLQ CX-24 does not include sexual desire, subjective arousal or orgasm, nor does it 
include items related to the relationship or partner, and as such does not represent a 
comprehensive measure of female sexual (dys)function.  However, as a disease-specific QOL 
module, it does include a number of important disease / treatment related mediating factors 
encountered in gynae-oncology (Table 4). 
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European Organisation for Research and Treatment of Cancer Quality of Life 
Questionnaire-Endometrial Cancer Module (EORTC QLQ EN-24) 
The Endometrial Cancer Module (EORTC QLQ EN-24) is a QOL measure developed for use 
in women treated for endometrial cancer [55]. The measure consists of 13 subscales 
including four subscales related to sexual/vaginal problems, sexual interest, sexual activity 
and sexual enjoyment.  
Multi-trait scaling analysis confirmed a hypothesised 13-subscale structure with internal 
consistency ranging from 0.74-0.86. Psychometric properties of the initial hypothesised scale 
for sexual functioning was poor, therefore sexual interest, sexual activity and sexual 
enjoyment were retained as 3 x single-item scales and sexual /vaginal problems as one multi-
item scale. As with the CX24, application of the COSMIN checklist led to a poor rating for both 
internal consistency and structural validity (Table 3) as the preferred analytical method, factor 
analysis, had not been used [42]. 
Despite an excellent rating for content validity using the COSMIN checklist, with item 
generation derived from literature review, patient and health professional interviews and 
expert panel consultations, the authors acknowledge that this QoL instrument does not 
represent a comprehensive measure of female sexual function [55].  
COSMIN criteria rated reliability fair, as details of time lapse and stability of participants 
between test-retest measurement points was absent (Table 3). Correlations ranged from 
0.81-0.92 for multi-item scales and from 0.72-0.97 for single item scales and criterion validity 
rated as good (Table 3). 
As with the CX-24, use of the COSMIN criteria rated cross-cultural validity poor as 
confirmatory factor analysis was not undertaken and results from individual country samples 
not reported. However, item generation and cognitive testing was undertaken in samples of 
women from 8 European countries, Australia and Taiwan together with international expert 
panel consultation [55] and the EN-24 subsequently validated for use in a Polish sample [56].  
Known group comparison of the sexuality single items discriminated between patient 
groups with high versus low Karnofsky performance scores, but no between group difference 
found for sexual/vaginal problems and sexual enjoyment scales. 
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In respect of clinical utility, the EN-24 measures sexual desire, objective arousal (lubrication), 
sexual satisfaction, sexual pain and some mediating factors (Table 4). However, like the CX-
24, it omits subjective arousal, orgasmic changes and does not include partner items or pre-
treatment comparators.  
The instrument can be completed in approximately 15 mins, but the scoring template requires 
reverse scoring for two items, linear transformation to a 0-100 scale and calculation of mean 
scores for multi-item scales in accordance with the scoring manual. As this is a QOL 
instrument, clinical cut off scores for diagnostic purposes are not appropriate.  
Future studies are required to evaluate the responsiveness of the instrument and, as 
with other instruments reviewed, it is not suitable for sexually inactive women, irrespective of 
cause, having observed a 74% non-completion rate for sexuality subscales.  
 
Sexual function-Vaginal changes Questionnaire (SVQ)  
The sexual function-vaginal changes questionnaire (SVQ) consists of 27 items [57]. Twenty 
core items measure sexual interest, lubrication, vaginal dimensions, dyspareunia, intimacy, 
sexual activity, orgasm, sexual problems in partner, sexual satisfaction and body image. 
Seven additional change items are included to capture the patient’s perception of changes 
between pre-treatment and post-treatment levels of sexual and vaginal problems.  
Five scales hypothesised were intimacy (IN), sexual interest (SI) and global sexual 
satisfaction (GS), with two additional scales for sexually active respondents: vaginal changes 
(VC) and sexual functioning (SF). Internal consistency (Cronbach’s alpha 0.76-0.83 for 
subscales) and structural validity rated fair in accordance with COSMIN guidelines, as the 
percentage and specific management of missing data items was not reported. Furthermore, 
the authors observed potential local dependency between the SF and GS scales.  
Content validity was rated excellent, although authors noted that the terminology used may be 
inherently heterosexist and excluded solo sexual expression.  
Reliability was rated poor as inter-rater reliability (patient response scores versus research 
interview observer scores for same items) was only reported for a sub-set of patients in study 
1  (n=75) and no test-retest reliability results given for the main validation sample (study 2 
n=257).  While responsiveness to change was not reported in this main validation paper, 
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evidence of satisfactory sensitivity and responsiveness was reported previously [58].This 
instrument was validated in a cervical cancer patient sample and, as with other instruments 
reviewed, two subscales could only be answered by women who had been sexually active in 
the last month. 
In terms of cross-cultural validation, the instrument was backwards and forwards 
translated from Danish to English as per EORTC translation guidelines, for validation in a 
Danish sample. More recently the SVQ has been validated in a sample (n=75) of Hong Kong 
Chinese women with gynaecological cancer [59].  
From a clinical perspective, the SVQ does not have a published scoring template or a 
clinical cut-off score for diagnostic purposes and no participant completion times or 
acceptability were reported, although the Chinese validation paper average completion time 
was 13 minutes [59]. Furthermore, this instrument includes clinically relevant mediating 
factors including vaginal changes, body image concerns, partner interest in sexual contact 
and pre-treatment sexual function comparator items (Tables 4 & 5).   
  
Gynaecologic Leiden Questionnaire (GLQ) 
The Gynaecologic Leiden Questionnaire measures sexual function and vaginal changes for 
women with gynaecological cancer [60].  There are three domains within the questionnaire; 
Female Sexual Complaints (FSC) three items; Female Sexual Function (FSF) four items; 
Female Orgasm (FO) one item.  
The validation sample consisted of 66 cervical cancer patients, 66 women attending a 
sexology service and 66 controls (n=198). Inter-scale correlations computed for the three 
groups ranged from 0 to 0.53, although results indicated that GLQ subscales did not measure 
totally independent constructs. According to COSMIN criteria, the measure rated as good for 
internal consistency (0.73 to 0.80) and structural validity, (total variance explained by the 
three-factor structure was 71% for the ONCO group). Test re-test reliability of 0.78-0.93 
(mean 2.8 weeks, SD1.7, range 1-8 weeks) was rated as good, but was only tested in the 
control group. Responsiveness was rated fair as, while subscale scores demonstrated 
sensitivity to change before and after cervical cancer treatment, stability of other factors likely 
to affect sexual function during this time was not reported. 
15 
 
Scores from the three subscales differentiated well between women treated for cervical 
cancer, those attending the sexology service and control group participants. However, the 
GLQ rated poor for hypothesis testing, no a priori hypotheses were stated and appropriate 
comparator measures used solely in the sexology clinic sub-sample. Although the 
questionnaire was translated into English, the instrument has only been validated in a Dutch 
language sample to date.  
In terms of clinical utility, the GLQ scoring system is not easy to use and, as with all 
but one of the reviewed instruments, no clinical cut off score is available to date.  
The measure contains a number of clinically relevant mediating factors including vaginal 
changes and partner items, but may not be fully inclusive of  solo sexual expression or same 
sex sexual activity. Furthermore, in the final validated 8-item measure, subjective arousal and 
orgasm, independent of intercourse, were not included. As with other instruments reviewed, 
this measure does not adequately evaluate the concept of sexual dysfunction in women who 
are sexually inactive.  
 
Discussion 
When identifying a suitable instrument for sexual morbidity research in oncology, researchers 
primarily consider which patient-reported outcome measures (PROMS) generate the most 
valid and reliable data. Currently there is no single self-report measure in use within cancer 
clinical trials that incorporates broader (physical, emotional and relational) aspects of sexual 
health or well-being for people of either gender affected by cancer [61]. 
Selection of an instrument for clinical use, where assessment informs decisions about 
clinical management and onward referral, means that there should be no clinically important 
omissions and items / domains should represent contemporary definitions of female sexual 
dysfunction as well as being valid and reliable from a psychometric perspective [32]. While 
disease-specific QOL instruments with sexuality sub-scales may be useful to screen for the 
presence of treatment-induced sexual difficulties- they often lack the measurement precision 
on which to base diagnostic or clinical management decisions.   
Furthermore, while female sexual (dys) function after cancer treatment has some anatomical 
and physiological constants, this complex and multi-faceted concept is a social construct. The 
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assessment (or measurement) of FSD must therefore evolve in scope, definition and 
terminology across cultures and across time.  Hence research and clinical instruments 
developed and in common use in earlier published studies are not always fit for purpose 
regarding current norms for sexual attitudes, behaviour, identities, relationships or in relation 
to the impact of contemporary multi-modal cancer treatment. 
Recognition of the limitations in many self-report measures of sexual function and 
satisfaction for people affected by cancer has led to important American and European 
instrument development initiatives. The US National Institutes of Health PROMIS network 
have validated a suite ( SexFS v.2.0) of customisable self-report items and domains for use in 
cancer and other male and female populations, sexually active with and without a partner 
[40,41]. Furthermore, the EORTC Quality of Life Group is developing a sexual health module 
suitable for all primary diagnostic groups in oncology. This new EORTC module addresses 
the limited scope of previous site-specific QoL modules [61]. 
It is interesting to note that despite four [24,49,55,57] of the six instruments achieving 
an “excellent” rating for content validity (Table 3), five [47,49,55,57,60] of the six instruments 
reviewed omitted one or more dimension of female sexual function. The QLQ CX-24 omits 
sexual desire, only the FSFI includes items addressing both subjective and objective aspects 
of sexual arousal, and half of the instruments reviewed [47,49,55] do not evaluate orgasmic 
changes (Table 4).  
While the instruments measured global sexual satisfaction, or satisfaction with specific 
aspects of sexual response, distress or bother associated with sexual changes or difficulty 
was explicitly measured by the SVQ alone, in keeping with latest DSM V diagnostic criteria for 
sexual disorders [32]. The presence or absence of emotional distress (or bother) associated 
with changes in sexual function or expression is an important clinical diagnostic threshold for 
management decisions. Hence, as sexual inactivity is not itself problematic, clinical and 
research instruments should measure the extent to which people are distressed or avoid 
sexual contact because of changes in sexual function or well-being [62]. 
Sexual inactivity over the instrument recall period (usually 4 weeks) is an important research 
and clinical consideration affecting the validity of most sexual morbidity instruments. Scoring 
inconsistencies or lower scoring validity occurs when sexually inactive participants are 
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included, as the instrument cannot distinguish between low scoring women sexually inactive 
as a direct consequence of treatment / disease induced sexual difficulties, versus those 
sexually inactive for unrelated reasons. Baser et al [24] remark that it is important from a 
psychometric perspective that any scale score of zero to an item explicitly relates to the 
severity of dysfunction assessed by those items / scales. Some of the instrument structures 
(SVQ and EORTC modules) offer a reduced item or domain set for sexually active 
respondents. However, this instrument structure may result in significantly reduced sample 
numbers of sexually active women for individual domain or item validation purposes [49, 55]. 
Clinically, the normal recall period of 4 weeks may be too short, particularly for older women / 
couples who are sexually active but at intervals in excess of 4 weeks. 
In using the COSMIN checklist as recommended [27,42] we found that none of the 
papers reported measurement error, data on responsiveness was available for only two 
instruments [58,60] and half of the papers reviewed failed to report on criterion validity [24, 
57, 60]. Furthermore, test-retest reliability reporting was inconsistent, with a tendency to omit 
details of time lapse and stability of participant’s health status between measurement points 
(Table 3). Cross-cultural validity for EORTC instruments achieved a poor rating, despite being 
the only instruments in which cross-cultural development / cognitive testing was routinely 
included at the instrument development stage [63]. The poor COSMIN rating arose from 
failure to report results from individual countries and an inadequate sample size for some 
country sub-groups [42]. 
Clinical Utility 
In reviewing the conceptual scope of these instruments, only the SVQ and SABIS-G included 
pre-treatment sexual function comparisons, despite clinical recognition that pre-treatment 
sexual function or well-being is frequently affected by presenting disease symptoms (e.g. 
vaginal bleeding / sexual pain) and hence rarely represents a true baseline measure [22]. 
Four [49,55,57,60] of the six instruments included commonly encountered mediating 
treatment or illness effects (Table 4) such as vaginal changes, menopause and altered body 
image or femininity. Despite the use of PROMS to monitor changes in severity or duration of 
symptoms over time, particularly in response to an intervention, none of the instruments 
included items regarding the effect of therapeutic aids. When considering management and 
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referral options it is often helpful for clinicians to review compliance and efficacy of biomedical 
strategies (HRT, lubricants, moisturisers, and dilators), sexual aids (vibrators, clitoral vacuum 
devices) or specialist services (gynaecologist, sexual counselling, and medical sexology). 
Although partner and relationship items were absent from both QOL instruments, this 
important contributory factor to women’s sexual recovery was included in the content of the 
four sexual morbidity instruments reviewed. Sexual morbidity PROMS terminology continues 
to privilege heterosexual penile-vaginal intercourse as the dominant sexual activity. None of 
the instruments reviewed were explicitly inclusive of solo sexual expression, nor validated in a 
sample of non-heterosexual women. 
As open access and remote (on-line / mobile apps / telephone clinics) follow-up 
systems are used increasingly to manage service access for the exponential increase in 
cancer survivors, within finite resources, clinicians will need to become more familiar with the 
selection and use of self-report measures for remote monitoring of treatment late effects and 
their management [26]. Hence, adequate investment in the development and integration of 
automated IT systems to collect and analyse “real time” PROMS data will be increasingly 
important if patients and clinicians are to benefit fully from routine PROMS data use.  
The ideal clinical instrument should be brief and easy to complete and score to minimise 
burden for the patient and health professional, while still generating meaningful data [34]. 
None of the instruments reviewed exceeded 24 items, but only two [49,55] out of six papers 
reported completion time and participant feedback on ease of use (Table 5).  
Five [47,49,55,57,60] of the six instrument scoring templates were complex or time-
consuming for self or clinical interpretation and the absence of a clinical cut-off score for all 
but one instrument (FSFI) limits diagnostic and clinical management utility. However, all of the 
instruments have some application in both remote monitoring systems or as a vehicle for 
structured clinical discussion given the low levels of routine assessment of FSD, even in high-
risk patient groups [11,64].  
Conclusion 
The findings of this review suggest that the Female Sexual Function Index (FSFI) remains the 
most robust female sexual morbidity outcome measure, for research or clinical use, in 
sexually active women treated for cervical or endometrial cancer. However, development of 
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an instrument that measures sexual dysfunction in women who are infrequently / not sexually 
active due to treatment consequences is still required to identify women in need of further 
support and sexual rehabilitation. 
Increasing the use of valid and reliable sexual morbidity PROMS in routine clinical 
practice, and in survivorship research, is imperative if we are to improve the identification and 
management of treatment-induced sexual difficulties associated with current and emerging 
treatments. While female sexual difficulties remain an embarrassing and challenging aspect 
of recovery after cancer for many clinicians and patients, the appropriate use of validated 
screening tools and PROMS such as the FSFI may yet prove invaluable in helping to target 
self-management strategies and scarce sexual rehabilitation resources to women and 
couples most in need.       
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Research Highlights 
•No instrument reviewed included all pertinent physical, emotional and relational impacts on 
sexual well-being after cancer  
•Measuring sexual dysfunction in women who are not sexually active due to treatment 
consequences remains problematic 
•The Female Sexual Function Index is the most suitable PROM for sexual morbidity 
measurement in gynae-oncology practice 
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Figure 1: Flow chart for search strategy 
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Table 1: Summary of Full Search Strategy 
 
("quality of life" OR "health related quality of life").ti,ab  
 
OR  (Sex* OR "Sexual difficult*" OR "Sexual dysfunct" OR "Sexual funct*" OR "Sexual 
morb*" OR "Sexual behav*").ti,ab  
  
AND (Questionnaire OR Measure* OR Instrument OR Assessment OR Tool OR outcome 
OR "Outcome assessment" OR "Outcome measure*").ti,ab   
 
AND (Validation AND stud* OR Psychometr* OR Valid* OR Reliab* OR Reproducib* OR 
"Reproducibility of results" OR "Discriminant analysis" OR Coefficient OR "internal 
consistency" OR alpha OR item OR correlation* OR factor AND analys* OR subscale OR 
multi-trait OR error OR sensitiv* OR responsive* OR Rasch OR Cronbach* AND alpha OR 
factor AND structure OR test AND retest).ti,ab  
  
AND (Female OR Women OR Woman).ti,ab   
All searches [Limit to: English Language and Female and Humans and Publication 
Years 1990-2015] 
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Table 2: Summary of included studies  
 
Measure Study 
Details 
(authors, 
date) 
Country of 
Origin 
Cancer or 
disease 
specific 
measure 
Assessment 
focus: FSD or 
QOL measure 
Assesses 
only 
sexually 
active 
patients 
Domain Names  
(number of items) 
Total 
number 
of items 
Recall period Study 
Population 
Age range 
of sample 
(years) 
FSFI [24] 
 
Baser, Yuelin 
& Carter 
(2012)    
 
USA Cancer  FSD Yes- women 
with no 
recent 
sexual 
activity 
excluded  
Desire (2) 
Arousal (4) 
Lubrication (4) 
Orgasm (3) 
Satisfaction (3) 
Pain (3) 
19 Past 4 weeks  Gynaecological, 
Cervical Cancer 
& Bone Marrow 
Transplant  
18-50 
SABIS-G 
[47] 
Ferguson, 
Urowitz, 
Massey et al. 
(2012) 
Canada  Gynaecological 
Cancer  
FSD (sexual 
adjustment) &  
Body Image  
No  Sexual Adjustment (4) 
Body Image (3)  
 
7  Since 
treatment 
Gynaecological  20-76 
EORTC 
QLQ CX-
24 [49] 
Greimel. 
Vlasic, 
Waldenstrom 
et al. (2006) 
7 European 
countries, 
Austria, 
Australia & 
Taiwan  
Cervical Cancer  QOL Yes- 
sexually 
active to 
answer 
sexual / 
vaginal 
function 
items  
Sexual/Vaginal 
Functioning (4)  
Sexual Worry (1) 
Sexual Activity (1) 
Sexual Enjoyment (1)  
Menopausal symptoms 
(1)  
Body Image (3) 
Symptom Experience 
(11)  
Lymphoedema (1) 
Peripheral Neuropathy 
(1)  
 
24  Past week for 
symptom / 
other items  
Past 4 weeks 
for sexual 
items  
Cervical Cancer 37-65 
EORTC 
QLQ EN-
24 [55] 
Greimel, 
Nordin, 
Lanceley et 
al.  
(2011) 
7 European 
countries, 
Austria, 
Australia & 
Taiwan 
Endometrial 
Cancer  
QOL Yes- 
sexually 
active to 
answer 
sexual/ 
vaginal 
problem 
Sexual/ Vaginal  
Problems (3) 
Sexual Interest (1) 
Sexual Activity (1) 
Sexual Enjoyment (1) 
Body Image  (2) 
Lymphoedema (2) 
24 Past week for 
symptom / 
other items  
Past 4 weeks 
for sexual 
items 
Endometrial 
Cancer 
35-87 
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items  Urological Symptoms 
(4) 
GI symptoms (5) 
Back / pelvic pain (1) 
Muscular / joint pain (1) 
Peripheral Neuropathy 
(1) 
Hair Loss (1) 
Taste Changes (1) 
 
SVQ [57] Jenson, Klee, 
Thranov et al.  
(2004) 
Denmark  Cervical, 
Endometrial & 
Ovarian Cancer  
FSD Yes- sexual / 
vaginal 
function 
items only 
answered by 
sexually 
active 
patients 
Sexual Interest (1) 
Intimacy (2) 
Sexual Functioning (3) 
Vaginal Changes (4) 
Global sexual 
satisfaction (2) 
Plus 8 non-scoring 
items 
 
20 
(plus 7 
change 
items) 
Past 4 weeks Cervical Cancer 23-80 
GLQ [60] Pieterse, Ter 
Kuile, Maas 
et al. (2008) 
Netherlands Cervical  FSD Yes- female 
orgasm & 
female 
sexual 
complaints 
domains 
only 
answered by 
sexually 
active 
patients  
Female Sexual 
Complaints (3) 
Female Sexual 
Function (4) 
Female Orgasm (1) 
Plus 3 non-scoring 
items  
11 Not reported Cervical cancer, 
sexology clinic 
attendees, 
healthy volunteer 
control group 
21->60 
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Table 3: Instrument Measurement Properties: Methodological Evaluation (COSMIN)  
 
 
Measure  Internal 
consistency 
Reliability Measurement 
Error 
Content  
Validity 
Structural 
validity 
Hypothesis  
Testing* 
Cross-cultural 
validity 
Criterion 
validity  
Responsiveness 
FSFI [24] Excellent  Not 
reported 
Not reported Excellent  Excellent  Good Not reported Not reported Not reported 
SABIS-G 
[47]  
Excellent  Fair Not reported Fair  Excellent  Fair Not reported Excellent Not reported 
EORTC 
QLQ CX-
24 [49] 
Poor (multi-
trait scaling 
analysis)  
Not 
reported 
Not reported Excellent  Poor (no factor 
analysis) 
Poor  Poor (didn’t use 
CFA)  
Good  Not reported 
EORTC 
QLQ EN-
24 [55] 
Poor (multi-
trait scaling 
analysis) 
Fair Not reported Excellent  Poor (no factor 
analysis) 
Good Not reported Good Not reported 
SVQ [57] Fair Poor (only 
inter-rater) 
Not reported Excellent Fair Not reported Not reported Not reported Reported in 
Jensen et al 
2003 
GLQ [60] Good Good Not reported Not reported Good Poor Not reported Not reported Poor 
 
* According to COSMIN guidance Hypothesis Testing refers to whether hypotheses were created a priori and whether the direction and expected magnitude 
of correlations were stated in the journal papers [36].  
 
CFA = Confirmatory Factor Analysis 
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Table 4: Conceptual scope of Instrument: extent to which instrument measures dimensions of FSD and includes key mediating factors   
 
 
Key: 
• Concept measured 
X Concept not measured 
 
 
 
 
 
 Dimensions of FSD Mediating Factors 
Measure  Sexual 
Desire 
 
Sexual Arousal 
(Subjective / 
Objective   
Orgasm  Sexual 
Satisfaction 
Sexual 
Pain 
Solo 
sexual 
expression  
Relationship 
/ partner  
Body 
image / 
femininity  
Distress 
/ Bother 
Pre-
treatment 
comparator 
of sexual 
function 
Treatment 
Impact (s) 
on altered 
sexual 
wellbeing  
Sexual 
Aids 
Use 
Specialist 
Service 
Use  
Sub Obj 
FSFI [24] •   •  •  •  •  •  •  •  X X X X X X 
SABIS-G 
[47] 
•  X X X •  X X •  •  X •  X X X 
EORTC 
QLQ CX-24 
[49] 
X X •  X •  •  X X •  X X •  X X 
EORTC 
QLQ EN-24 
[55] 
•  X •  X •  •  X X •  X X •  X X 
SVQ [57] •  X •  •  •  •  X •  •  •  •  •  X X 
GLQ [60] •  X •  •  •  •  •  •  X X X •  X X 
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Table 5: Clinical Utility Criteria 
 
Measure  Length of 
instrument  
Completion 
time (mins)  
Complexity  Patient self-report 
or researcher 
administered  
Clinical cut off 
scores  
Patient or HCP 
user ease of use 
feedback  
Score  
(out of 6)  
FSFI [24] 19 items Not reported  Likert  
(5 item response)  
Patient self-report Cut off score ≤ 26 
considered 
diagnostic of FSD 
Not reported  5 
SABIS-G [47] 7 items Not reported  Likert  
(5 item response), 
scoring system 
complex  
Patient self-report  No Not reported 2  
EORTC QLQ 
CX-24 [49] 
24 items  < 15 mins  Likert  
(4 item response) 
scoring system 
complex 
Patient self-report  Not applicable Majority completed 
under 15 mins and 
90% of sample 
reported questions 
are clear and easy 
to understand 
4  
EORTC QLQ 
EN-24 [55] 
24 items  15 mins  Likert  
(4 item response), 
scoring system 
complex 
Patient self-report  Not applicable Majority completed 
under 15 mins and 
90% of sample 
reported questions 
are clear and not 
upsetting 
4 
SVQ [57] 20 items  Not reported  Likert 
no scoring template   
Patient self-report  No Feasible for self-
assessment and 
high participation 
rate  
3 
GLQ [60] 11 items Not reported  Likert  
(5 item response) 
scoring system 
complex 
Patient self-report No Not reported 2 
 
 
